NEW
Font size
WorksheetsDay 2 ENT Flashback
Total questions: 15
Worksheet time: 10mins
Which of the following statement is TRUE about the rationale of targeted 200mg BD dosage of sacubitril/valsartan?
To deliver similar exposure as Valsartan (Diovan) 80mg BD
To ensure a 24-hour neprilysin enzyme inhibition
To deliver a maximal 80% neprilysin enzyme inhibition
To achieve a higher mean daily dose than doses used in Val-HeFT
Which of the following is/are recommended by the 2017 updated ACC/AHA/HFSA guideline for the Management of Chronic Heart Failure (HF)?
I. ACE inhibitor
II. Diuretics
III. ARNI
IV. SGLT2
I & II
I & III
I, II & III
All of the above
Which of the following biomarker was increased in HF patients treated on sacubitril/valsartan?
BNP & cGMP
NT-proBNP & troponin
BNP & troponin
NT-proBNP & troponin
Compared to enalapril, sacubitril/Valsartan resulted in greater reduction in all cause mortality. Its NNT was ____?
16
21
31
36
How many percentages of patients in PARADIGM-HF were Asian
15%
18%
19%
21%
In PARADIGM-HF, as compared to enalapril, sacubitril/valsartan was more effective in reducing
RRR of death from CV causes by 21%
RRR of first HF hospitalization by 21%
RRR of sudden cardiac death by 16%
RRR of all-cause death by 20%
Initiation of sacubitril/valsartan in-hospital led significantly greater reduction in NT-proBNP versus enalapril with _____ of relative risk reduction after 8 weeks of follow up
26%
27%
28%
29%
Patients that are currently on ACE inhibitor are required to stop the drug for 36 hours before starting of Sacubitril/valsartan due to
Hypotension
Hyperkalaemia
Cough
Angioedema
The following are the contraindications for sacubitril/valsartan EXPECT
End-stage renal disease
Concomitant used with Aliskiren
History of angioedema
Second and third trimester pregnancy
How many percentages of patients in PIONEER-HF trial were ACEi/ARB-naive?
52%
53%
54%
55%
Treatment with sacubitril/valsartan should not be initiated in patients with serum potassium level
>5.2 mmol/L
>5.4 mmol/L
≥5.2 mmol/L
≥5.4 mmol/L
Sacubitril is rapidly converted into its active metabolite, Sacubitrilat in
Kidney
Heart
Vascular
Liver
Which of the following statement is TRUE about the safety events based on the PARADIGM-HF trail?
Number of incidence of cough between patients on sacubitril/valsartan and enalapril were similar
Fewer patients on sacubitril/valsartan discontinued the study drug due to any adverse event as compared to enalapril
Significant higher number of patients were required to discontinue enalapril than sacubitril/valsartan due to hyperkalemia
Incidence of angioedema was numerically lower in patients on sacubitril/valsartan versus enalpril
How many percentages of patients in PARADIGM-HF trial were on diuretics and beta blockers at baseline?
90%, 83%
90%, 60%
80%, 93%
80%, 60%
In PARADIGM-HF trial, how many percentages of the patients were in respective NYHA class?
A
B
C
D
